Smith sells Perry for £31m
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Smith & Nephew, the healthcare group, has continued the tidying up of its portfolio of businesses with the sale of Perry, its US-based medical gloves operation, for £31m.
The disposal to Ansell, a division of Pacific Dunlop, involves a £19m write-off of goodwill paid at the time of original acquisition. A loss of £12m will be taken in Smith's next results.
Following the sale, Smith & Nephew is focused on five main product areas - wound management, casting and support, trauma, arthroscopy and orthopaedic implants. The company said it planned to concentrate on sophisticated products that would sell world-wide.
John Robinson, chief executive, said: "Perry helped to build the foundation for today's successful US operation. But in an increasingly competitive market, surgical gloves are not readily sold alongside our product range."
In 1994 Perry made profits of £3.4m on sales of £41m. For a period after the sale, Smith will continue to distribute Perry gloves outside the US and provide technical support to Ansell.
Two months ago, Smith announced a £5.5m loss after an exceptional charge of £177.7m, mainly on the sale of the US lens business, Ioptex. At the time the company said it was planning sizeable acquisitions to give it greater critical mass in the fast-changing global pharmaceuticals market.
Mr Robinson said the expansion would focus on the Asia-Pacific region.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments